Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.70 |
| ▸ | CA2 | P00918 | 2/20 | 0.70 |
| ▸ | CA12 | O43570 | 1/20 | 0.70 |
| ▸ | CA3 | P07451 | 1/20 | 0.70 |
| ▸ | CA4 | P22748 | 1/20 | 0.70 |
| ▸ | CA6 | P23280 | 1/20 | 0.70 |
| ▸ | CA5A | P35218 | 1/20 | 0.70 |
| ▸ | CA7 | P43166 | 1/20 | 0.70 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.70 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.70 |
| ▸ | CA9 | Q16790 | 1/20 | 0.70 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.70 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22905316 | 0.88 | CA1 (0.70) | CA1CA2CA12CA3CA4 | |
| SCHEMBL8205298 | 0.88 | CA12 (0.74) | CA1CA2CA12CA3CA4 | |
| SCHEMBL1697369 | 0.88 | CA12 (0.74) | CA1CA2CA12CA3CA4 | |
| SCHEMBL47275 | 0.88 | CA12 (0.74) | CA1CA2CA12CA3CA4 | |
| SCHEMBL20485574 | 0.88 | CA12 (0.54) | CA1CA2CA12CA3CA4 | |
| SCHEMBL18529948 | 0.88 | CA12 (0.54) | CA1CA2CA12CA3CA4 | |
| SCHEMBL12840779 | 0.86 | CA1 (0.52) | CA1CA2CA12CA3CA4 | |
| SCHEMBL12240240 | 0.85 | CA12 (0.74) | CA1CA2CA12CA3CA4 | |
| SCHEMBL2606494 | 0.85 | CA12 (0.74) | CA1CA2CA12CA3CA4 | |
| SCHEMBL2742289 | 0.85 | CA12 (0.74) | CA1CA2CA12CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533345-B2 | Rufinamide for use in the treatment of myotonia | AARHUS UNIVERSITET (DK) | 2026-01-27 | — | — | US | disclosed |
| US-20240307357-A1 | RUFINAMIDE FOR USE IN THE TREATMENT OF MYOTONIA | AARHUS UNIVERSITET (DK) | 2024-09-19 | — | — | US | disclosed |
| US-12023322-B2 | Rufinamide for use in the treatment of myotonia | AARHUS UNIVERSITET (DK) | 2024-07-02 | — | — | US | disclosed |
| US-11278502-B2 | Modified release formulation of lacosamide | LUPIN LIMITED (IN) | 2022-03-22 | — | — | US | disclosed |
| EP-3386491-B1 | RUFINAMIDE FOR USE IN THE TREATMENT OF MYOTONIA | UNIV AARHUS (DK) | 2021-12-08 | — | — | EP | disclosed |
| US-10786464-B2 | Modified release formulation of lacosamide | LUPIN LIMITED (IN) | 2020-09-29 | — | — | US | disclosed |
| EP-2496220-B1 | MODIFIED RELEASE FORMULATION OF LACOSAMIDE | LUPIN LTD (IN) | 2019-10-16 | — | — | EP | disclosed |
| US-20190029968-A1 | MODIFIED RELEASE FORMULATION OF LACOSAMIDE | LUPIN LIMITED (IN) | 2019-01-31 | — | — | US | disclosed |
| US-20180369207-A1 | RUFINAMIDE FOR USE IN THE TREATMENT OF MYOTONIA | AARHUS UNIVERSITET (DK) | 2018-12-27 | — | — | US | disclosed |
| EP-2496220-A1 | MODIFIED RELEASE FORMULATION OF LACOSAMIDE | Lupin Limited (IN) | 2012-09-12 | — | — | EP | disclosed |
| US-20120219631-A1 | MODIFIED RELEASE FORMULATION OF LACOSAMIDE | LUPIN LIMITED (IN) | 2012-08-30 | — | — | US | disclosed |
| WO-2011055385-A1 | MODIFIED RELEASE FORMULATION OF LACOSAMIDE | LUPIN LIMITED (IN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307357-A1 | RUFINAMIDE FOR USE IN THE TREATMENT OF MYOTONIA | MYOF, CKMT1A; CKMT1B, MTPN | CA1 3809/4885CA2 1757/4885CA12 3590/4885 |
| US-20180369207-A1 | RUFINAMIDE FOR USE IN THE TREATMENT OF MYOTONIA | MYOF, CKMT1A; CKMT1B, MTPN | CA1 3834/4885CA2 1709/4885CA12 3157/4885 |
| US-12533345-B2 | Rufinamide for use in the treatment of myotonia | CKMT1A; CKMT1B, CPT1B, MYLK2 | CA1 2129/4885CA2 513/4885CA12 1623/4885 |
| US-12023322-B2 | Rufinamide for use in the treatment of myotonia | MYOF, CKMT1A; CKMT1B, MTPN | CA1 3834/4885CA2 1709/4885CA12 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.